Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBS314 in Relapsed/Refractory Multiple Myeloma
NCT06232096Phase 2Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MBS314 in multiple myeloma (MM), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoints: Percentage of Participants with Adverse Events up to 29 months, Incidence of Dose Limiting Toxicities up to 4 weeks and 3 more. Started Feb 2024; status: recruiting.
02
Drugs
MBS314
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06232096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232096.